Correction to: Amphetamine extended-release oral suspension (Adzenys ER™) and orally disintegrating tablets (Adzenys XR-ODT®) in attention-deficit hyperactivity disorder: a profile of their use
نویسندگان
چکیده
منابع مشابه
NEW DRUG APPROVALS Adzenys XR-ODT for ADHD
NEW DRUG APPROVALS Adzenys XR-ODT for ADHD The FDA has given the green light to Adzenys XR-ODT (Neos Therapeutics) for the treatment of attention -deficit/ hyperactivity disorder (ADHD) in patients 6 years of age and older. With this approval, the product is the first extended-release orally disintegrating tablet (ODT) for this indication. Adzenys XR-ODT contains amphetamine loaded onto a mixtu...
متن کاملPharmacokinetics of a New Amphetamine Extended-Release Oral Suspension in Children with Attention-Deficit/Hyperactivity Disorder.
OBJECTIVE An extended-release amphetamine (AMP) oral suspension has been developed to facilitate medication ingestion and dose titration. This study sought to determine the pharmacokinetic (PK) profile of this new formulation in children with attention-deficit/hyperactivity disorder (ADHD). METHODS This was an open-label, single-period, PK study in 29 pediatric participants with ADHD. Partici...
متن کاملPharmacokinetics of a Novel Amphetamine Extended-Release Orally Disintegrating Tablet in Children with Attention-Deficit/Hyperactivity Disorder.
BACKGROUND A novel formulation for treating attention-deficit/hyperactivity disorder (ADHD) has recently been developed-amphetamine extended-release orally disintegrating tablets (AMP XR-ODTs). In this study, we assessed the rate of absorption and exposure of AMP XR-ODT under fasted conditions in children with ADHD. METHODS Children (6-12 years) with ADHD were enrolled in a single-dose, open-...
متن کاملARICEPT Tablets and ARICEPT Orally Disintegrating Tablets (ODT). ARICEPT
----------------------------RECENT MAJOR CHANGES-------------------- Addition of new dosage strength: ARICEPT 23 mg ----------------------------INDICATIONS AND USAGE--------------------- ARICEPT is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s Disease (1.0).
متن کاملProfile of guanfacine extended release and its potential in the treatment of attention-deficit hyperactivity disorder
The α2-adrenergic receptor agonist guanfacine, in its extended-release formulation (GXR), is the most recent nonstimulant medication approved in several countries for the treatment of attention-deficit hyperactivity disorder (ADHD) as monotherapy and as adjunctive pharmacotherapy to stimulants in children and adolescents. The present paper aims to review comprehensively and critically the pharm...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Drugs & Therapy Perspectives
سال: 2018
ISSN: 1172-0360,1179-1977
DOI: 10.1007/s40267-018-0567-2